Akebia Therapeutics Inc (AKBA)
1.155
+0.02
(+1.32%)
USD |
NASDAQ |
May 17, 16:00
1.155
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Gross Profit (TTM): 121.66M for March 31, 2024
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 121.66M |
December 31, 2023 | 120.48M |
September 30, 2023 | 142.16M |
June 30, 2023 | 128.55M |
March 31, 2023 | 197.22M |
December 31, 2022 | 207.76M |
September 30, 2022 | 158.60M |
June 30, 2022 | 180.98M |
March 31, 2022 | 73.64M |
December 31, 2021 | 60.98M |
September 30, 2021 | 43.16M |
Date | Value |
---|---|
June 30, 2021 | 39.99M |
March 31, 2021 | -44.90M |
December 31, 2020 | -1.833M |
September 30, 2020 | 37.34M |
June 30, 2020 | 61.41M |
March 31, 2020 | 209.02M |
December 31, 2019 | 189.66M |
September 30, 2019 | 210.34M |
June 30, 2019 | 209.79M |
March 31, 2019 | 195.45M |
December 31, 2018 | 199.97M |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (TTM) Range, Past 5 Years
-44.90M
Minimum
Mar 2021
210.34M
Maximum
Sep 2019
117.30M
Average
125.11M
Median
Gross Profit (TTM) Benchmarks
Aquestive Therapeutics Inc | 31.02M |
Amicus Therapeutics Inc | 379.54M |
Insmed Inc | 246.29M |
Altimmune Inc | -- |
InfuSystems Holdings Inc | 64.04M |